scPharmaceuticals Secures Five New Patents for Heart Failure Drug SCP-111
核心洞察
scPharmaceuticals received five Notices of Allowance from the USPTO for patent applications covering their furosemide formulation SCP-111, designed to treat edema in heart failure and chronic kidney disease patients.
The new patents will join four existing patents covering SCP-111, strengthening the company's intellectual property portfolio as they prepare to file a supplemental NDA this quarter.
CEO John Tucker emphasized that securing additional patent protection represents a key strategic achievement that supports advancement of next-generation formulations and reinforces commitment to delivering transformative patient outcomes.
scPharmaceuticals Inc. announced that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The Burlington, Massachusetts-based pharmaceutical company is developing SCP-111 to treat edema in patients with heart failure or chronic kidney disease, with plans to file a supplemental New Drug Application (sNDA) this quarter.
Strengthening Intellectual Property Portfolio
The five new patents, once issued, will join four additional patents already owned by the company that cover the SCP-111 formulation, bringing the total patent protection to nine patents for this therapeutic candidate. This expanded intellectual property portfolio represents a significant milestone for the cardiorenal-focused pharmaceutical company.
"These allowances are vital developments in scPharmaceuticals' pursuit to provide effective care to patients suffering from edema due to heart failure or chronic kidney disease," said John Tucker, Chief Executive Officer of scPharmaceuticals. "Securing additional patent protection represents a key strategic achievement that strengthens the Company's intellectual property portfolio, which I believe supports the advancement of next-generation formulations and reinforces our commitment to delivering transformative outcomes for patients while expanding market opportunities."
Regulatory Timeline and Commercial Strategy
The company expects to file the supplemental NDA for SCP-111 during the current quarter, marking a critical regulatory milestone in the drug's development pathway. SCP-111 represents part of scPharmaceuticals' broader strategy to advance cardiorenal care through innovative, integrated treatments that address unmet patient needs.
The company's existing commercial portfolio includes FUROSCIX, and the forward-looking statements indicate ongoing development of products such as an Autoinjector designed to increase patient care and enable treatment of fluid retention at home.
Company Focus and Mission
scPharmaceuticals positions itself as a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations. The company's mission focuses on advancing cardiorenal care through innovative, integrated treatments, with a goal to become the foremost advocate for patient-centric cardiorenal care and drive global health improvements through specialized, multidisciplinary approaches.